Narcolepsy Type I as an autoimmune disorder

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Standard

Narcolepsy Type I as an autoimmune disorder. / Kornum, Birgitte Rahbek.

Handbook of Clinical Neurology. 1. ed. Elsevier, 2021. p. 161-172 (Handbook of Clinical Neurology, Vol. 181).

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Harvard

Kornum, BR 2021, Narcolepsy Type I as an autoimmune disorder. in Handbook of Clinical Neurology. 1 edn, Elsevier, Handbook of Clinical Neurology, vol. 181, pp. 161-172. https://doi.org/10.1016/B978-0-12-820683-6.00012-9

APA

Kornum, B. R. (2021). Narcolepsy Type I as an autoimmune disorder. In Handbook of Clinical Neurology (1 ed., pp. 161-172). Elsevier. Handbook of Clinical Neurology Vol. 181 https://doi.org/10.1016/B978-0-12-820683-6.00012-9

Vancouver

Kornum BR. Narcolepsy Type I as an autoimmune disorder. In Handbook of Clinical Neurology. 1 ed. Elsevier. 2021. p. 161-172. (Handbook of Clinical Neurology, Vol. 181). https://doi.org/10.1016/B978-0-12-820683-6.00012-9

Author

Kornum, Birgitte Rahbek. / Narcolepsy Type I as an autoimmune disorder. Handbook of Clinical Neurology. 1. ed. Elsevier, 2021. pp. 161-172 (Handbook of Clinical Neurology, Vol. 181).

Bibtex

@inbook{c824ae6e9c8b43fbb76925179402e406,
title = "Narcolepsy Type I as an autoimmune disorder",
abstract = "Narcolepsy Type 1 (NT1) is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the lateral hypothalamus. Ample genetic and epidemiologic evidence point in the direction of a pathogenesis involving the immune system. Many autoantibodies have been detected in blood samples from NT1 patients, but none in a consistent manner. Importantly, T cells directed toward hypocretin/orexin neurons have been detected in samples from NT1 patients. However, it remains to be seen if these potentially autoreactive T cells are also present in the hypothalamus and if they are pathogenic. For this reason, NT1 does still not fully meet the criteria for being classified as a genuine autoimmune disease, even though more and more results are pointing in that direction as will be described in this chapter. The autoimmune hypothesis has led to many attempts at slowing or stopping disease progression with immunomodulatory treatment, but so far the overall results have not been very encouraging. It is clear that more research into the pathogenesis of NT1 is needed to establish the precise role of the immune system in disease development.",
keywords = "Autoantibodies, Autoimmune, Hypocretin, Immune therapy, Narcolepsy, Orexin, Pathogenesis, T cells",
author = "Kornum, {Birgitte Rahbek}",
note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",
year = "2021",
doi = "10.1016/B978-0-12-820683-6.00012-9",
language = "English",
isbn = "978-0-12-820107-7",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "161--172",
booktitle = "Handbook of Clinical Neurology",
address = "Netherlands",
edition = "1",

}

RIS

TY - CHAP

T1 - Narcolepsy Type I as an autoimmune disorder

AU - Kornum, Birgitte Rahbek

N1 - Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021

Y1 - 2021

N2 - Narcolepsy Type 1 (NT1) is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the lateral hypothalamus. Ample genetic and epidemiologic evidence point in the direction of a pathogenesis involving the immune system. Many autoantibodies have been detected in blood samples from NT1 patients, but none in a consistent manner. Importantly, T cells directed toward hypocretin/orexin neurons have been detected in samples from NT1 patients. However, it remains to be seen if these potentially autoreactive T cells are also present in the hypothalamus and if they are pathogenic. For this reason, NT1 does still not fully meet the criteria for being classified as a genuine autoimmune disease, even though more and more results are pointing in that direction as will be described in this chapter. The autoimmune hypothesis has led to many attempts at slowing or stopping disease progression with immunomodulatory treatment, but so far the overall results have not been very encouraging. It is clear that more research into the pathogenesis of NT1 is needed to establish the precise role of the immune system in disease development.

AB - Narcolepsy Type 1 (NT1) is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the lateral hypothalamus. Ample genetic and epidemiologic evidence point in the direction of a pathogenesis involving the immune system. Many autoantibodies have been detected in blood samples from NT1 patients, but none in a consistent manner. Importantly, T cells directed toward hypocretin/orexin neurons have been detected in samples from NT1 patients. However, it remains to be seen if these potentially autoreactive T cells are also present in the hypothalamus and if they are pathogenic. For this reason, NT1 does still not fully meet the criteria for being classified as a genuine autoimmune disease, even though more and more results are pointing in that direction as will be described in this chapter. The autoimmune hypothesis has led to many attempts at slowing or stopping disease progression with immunomodulatory treatment, but so far the overall results have not been very encouraging. It is clear that more research into the pathogenesis of NT1 is needed to establish the precise role of the immune system in disease development.

KW - Autoantibodies

KW - Autoimmune

KW - Hypocretin

KW - Immune therapy

KW - Narcolepsy

KW - Orexin

KW - Pathogenesis

KW - T cells

U2 - 10.1016/B978-0-12-820683-6.00012-9

DO - 10.1016/B978-0-12-820683-6.00012-9

M3 - Book chapter

C2 - 34238455

AN - SCOPUS:85109099265

SN - 978-0-12-820107-7

T3 - Handbook of Clinical Neurology

SP - 161

EP - 172

BT - Handbook of Clinical Neurology

PB - Elsevier

ER -

ID: 276334243